-transparent.png){kind=logo}
Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. 2007
Sabahattin Kaymakoglu, and
Dilek Oguz, and
Gurden Gur, and
Selim Gurel, and
Ethem Tankurt, and
Galip Ersöz, and
Seren Ozenirler, and
Cem Kalayci, and
Sule Poturoglu, and
Yilmaz Cakaloglu, and
Atilla Okten
Istanbul University, Department of Gastroenterohepatology, Istanbul Medical Faculty, Capa, Istanbul, Turkey. kaymakoglus@hotmail.com
Forty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of <400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.
Related Publications
Sabahattin Kaymakoglu, and
Dilek Oguz, and
Gurden Gur, and
Selim Gurel, and
Ethem Tankurt, and
Galip Ersöz, and
Seren Ozenirler, and
Cem Kalayci, and
Sule Poturoglu, and
Yilmaz Cakaloglu, and
Atilla Okten
October 2007,
Journal of gastroenterology and hepatology,
Sabahattin Kaymakoglu, and
Dilek Oguz, and
Gurden Gur, and
Selim Gurel, and
Ethem Tankurt, and
Galip Ersöz, and
Seren Ozenirler, and
Cem Kalayci, and
Sule Poturoglu, and
Yilmaz Cakaloglu, and
Atilla Okten
January 2009,
Scandinavian journal of gastroenterology,
Sabahattin Kaymakoglu, and
Dilek Oguz, and
Gurden Gur, and
Selim Gurel, and
Ethem Tankurt, and
Galip Ersöz, and
Seren Ozenirler, and
Cem Kalayci, and
Sule Poturoglu, and
Yilmaz Cakaloglu, and
Atilla Okten
November 2006,
Gastroenterologia y hepatologia,
Sabahattin Kaymakoglu, and
Dilek Oguz, and
Gurden Gur, and
Selim Gurel, and
Ethem Tankurt, and
Galip Ersöz, and
Seren Ozenirler, and
Cem Kalayci, and
Sule Poturoglu, and
Yilmaz Cakaloglu, and
Atilla Okten
January 2007,
Acta gastro-enterologica Belgica,
Sabahattin Kaymakoglu, and
Dilek Oguz, and
Gurden Gur, and
Selim Gurel, and
Ethem Tankurt, and
Galip Ersöz, and
Seren Ozenirler, and
Cem Kalayci, and
Sule Poturoglu, and
Yilmaz Cakaloglu, and
Atilla Okten
April 2011,
Journal of hepatology,
Sabahattin Kaymakoglu, and
Dilek Oguz, and
Gurden Gur, and
Selim Gurel, and
Ethem Tankurt, and
Galip Ersöz, and
Seren Ozenirler, and
Cem Kalayci, and
Sule Poturoglu, and
Yilmaz Cakaloglu, and
Atilla Okten
July 2005,
Hepatology (Baltimore, Md.),
Sabahattin Kaymakoglu, and
Dilek Oguz, and
Gurden Gur, and
Selim Gurel, and
Ethem Tankurt, and
Galip Ersöz, and
Seren Ozenirler, and
Cem Kalayci, and
Sule Poturoglu, and
Yilmaz Cakaloglu, and
Atilla Okten
January 2005,
Lancet (London, England),
Sabahattin Kaymakoglu, and
Dilek Oguz, and
Gurden Gur, and
Selim Gurel, and
Ethem Tankurt, and
Galip Ersöz, and
Seren Ozenirler, and
Cem Kalayci, and
Sule Poturoglu, and
Yilmaz Cakaloglu, and
Atilla Okten
January 2019,
Infection and drug resistance,
Sabahattin Kaymakoglu, and
Dilek Oguz, and
Gurden Gur, and
Selim Gurel, and
Ethem Tankurt, and
Galip Ersöz, and
Seren Ozenirler, and
Cem Kalayci, and
Sule Poturoglu, and
Yilmaz Cakaloglu, and
Atilla Okten
October 2010,
Hepatobiliary & pancreatic diseases international : HBPD INT,
Sabahattin Kaymakoglu, and
Dilek Oguz, and
Gurden Gur, and
Selim Gurel, and
Ethem Tankurt, and
Galip Ersöz, and
Seren Ozenirler, and
Cem Kalayci, and
Sule Poturoglu, and
Yilmaz Cakaloglu, and
Atilla Okten
June 2005,
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
